Trial Profile
Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 10 Jun 2013 Actual end date changed from Oct 2012 to Jun 2013, as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2011 New trial record